Gaining Ground: Expanding Options for Advanced HCC

Dr. Ghassan Abou-Alfa leads a small panel including Dr. Robert Lewandowksi and Dr. Amit Singal in a multidisciplinary discussion of hepatocellular carcinoma and updates to the treatment armamentarium.

EP. 1: Overview of Hepatocellular Carcinoma Risk Factors

December 22nd 2022

Ghassan Abou-Alfa, MD leads Robert Lewandowski, MD, FSIR, and Amit Singal, MD in a discussion of the main risk factors for hepatocellular carcinoma.

EP. 2: Review of Curative Treatment Strategies for HCC

December 22nd 2022

The panel shares insight as to which patients might be candidates for curative therapies such as embolization techniques and liver transplant.

EP. 3: Child-Pugh Scoring System and Liver Function Assessment

January 5th 2023

Dr Singal reviews the Child-Pugh scoring system, then Dr Lewandowski discusses the importance of considering liver function as well as disease burden when selecting a treatment strategy.

EP. 4: Therapy for Locally Advanced HCC

January 5th 2023

Experts in hepatocellular carcinoma discuss treatment options for locally advanced disease.

EP. 5: The Advent of Systemic Therapy for HCC

January 12th 2023

Drs Singal and Lewandowski review use of tyrosine kinase inhibitors, sorafenib and lenvatinib, and discuss trials that combined systemic therapy with chemoembolization.

EP. 6: Immune Checkpoint Inhibitors in HCC

January 12th 2023

A multidisciplinary panel discusses use of immune checkpoint inhibitors in patients with advanced HCC.

EP. 7: Combination Therapy with Immune Checkpoint Inhibitors for HCC

January 19th 2023

A deeper dive on immune checkpoint inhibitors in HCC including review of the mechanisms of action of the IO agents.

EP. 8: IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC

January 19th 2023

The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.

EP. 9: Immune Checkpoint Inhibitors and Their Effects on Liver Function

January 26th 2023

Drs Abou-Alfa, Singal, and Lewandowski discuss use of immune checkpoint inhibitors and liver function.

EP. 10: Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints

January 26th 2023

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

EP. 11: Novel Strategies: Combining Systemic and Local Therapies

February 2nd 2023

Ghassan Abou-Alfa, MD, Robert Lewandowski, MD, FSIR, and Amit Singal, MD discuss potential novel combination therapies including immune checkpoint inhibitors plus tyrosine kinase inhibitors plus local-regional therapeutic strategies.

EP. 12: HCC International Clinical Trials

February 2nd 2023

Closing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.